Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants

Completed · Phase 1 · Has a placebo group

Conditions studied: Human Parainfluenza Virus 2

In brief

Human parainfluenza virus type 2 (HPIV2) can result in severe respiratory illness in infants and young children. This study will test the safety of and immune response to an HPIV2 vaccine aimed at infants and children.

Key facts

Study ID

NCT01139437

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

45

Starts

2010-06-01

Expected to finish

2015-09-01

Last updated by the study team

2017-04-04

Who can join

Age: 1 and older, up to 49. Sex: any. Healthy volunteers: accepted.

Where it is running

• Johns Hopkins University, Bloomberg School of Public Health — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.